Pharmaceutical Committee

The Pharmaceutical Committee represents the innovative American pharmaceutical industry in the Netherlands. It contributes to the health and welfare of Dutch citizens by enabling availability and access to innovative medicines. The products represent an important investment in public health, enabling patients to live healthier and longer. As an industry, the pharmaceutical companies make a substantial contribution to employment, education and research in Dutch society.

For more information on the activities of the Pharmaceutical Committee, please visit the Committee's website. 

Current Committee Members:

• Roland Zegger (Chairman)
  General Manager
  Abbott B.V.  

   

• Mr. Tjerk Balk
  Country Director Netherlands
  Biogen Idec International B.V.

    

• Marcel M. Joachimstahl
  Vice President / General Manager
  GlaxoSmithKline B.V.

   

• Paul Korte
  General Manager
  Janssen-Cilag B.V.

   

• Alex Leather
  General Manager
  Amgen BV

   

• Andrew Oxtoby
  General Manager
  Eli Lilly Nederland BV

   

• Rob van Aperen
  General Manager
  Pfizer B.V.

   

• Guus van der Vat
  Managing Director
  Merck Sharp & Dohme BV

Affiliated companies are:

• Abbott B.V.                                               
  www.abbottlabs.nl & www.abbott.com

• Amgen B.V.
  www.amgen.nl & www.amgen.com 

• Biogen Idec International B.V.
  www.biogenidec.nl

• Bristol-Myers Squibb B.V.                     
  www.b-ms.nl & www.bms.com

• Eli Lilly Nederland BV                                                     
  www.lilly.nl

•  Gilead Sciences Netherlands B.V.
  www.gilead.com

• GlaxoSmithKline B.V.                             
  www.gsk.nl

• Janssen-Cilag B.V.                                 
  www.janssen-cilag.nl

• Merck Sharp & Dohme B.V. (MSD B.V.)      
  www.msd.nl

• Pfizer B.V.                                                  
  www.pfizer.nl